Company Overview and News

 
Pasukhas trending sideways, says AllianceDBS Research

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): AllianceDBS Research said Pasukhas Group Bhd (Pasukgb) had on Sept 13 settled at the day’s high of 11.5 sen (up 0.5 sen or 4.54%).
0177

 
Pasukhas up 4.54% on bagging RM20.44 million contract

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): Pasukhas Group Bhd rose 4.54% this morning after it secured a contract to sell a vessel of steam coal in South Kalimantan, Indonesia for US$4.93 million (RM20.44 million).
0177

 
Trading ideas: Sapura Energy, Unisem, Sunway, MyEG, Pasukhas, Magni-tech

2018-09-13 thestar.com.my
KUALA LUMPUR: Sapura Energy Bhd , Unisem (M) Bhd , Sunway Bhd , MY E.G. Services Bhd (MyEG), Pasukhas Group Bhd and Magni-Tech Industries Bhd are among the stocks to watch, according to JF Apex Research.
0177 7087

 
Pasukhas wins RM20mil contract

2018-09-13 thestar.com.my
Its wholly-owned Pasukhas Products Sdn Bhd inked the contract yesterday, said the construction company which recently diversified into coal trading
0177

 
KLCI to track global markets, edge higher on bargain hunting

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI is expected to edge higher on some bargain hunting activities, in line with the overnight gains at most global markets.
0177 5260 7087

 
FGV, Sapura Energy, Unisem, Sunway, MyEG, Pasukhas, Vertice, Land & General, OWG, MMAG and Magni-Tech

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (Sept 13) may include the following: FGV Holdings Bhd, Sapura Energy Bhd, Unisem (M) Bhd, Sunway Bhd, MY E.G. Services Bhd, Pasukhas Group Bhd, Vertice Bhd, Land & General Bhd, Only World Group Holdings Bhd, MMAG Holdings Bhd and Magni-Tech Industries Bhd.
0177 5260 7087

 
Pasukhas bags RM20m steam coal sales contract

2018-09-12 theedgemarkets
KUALA LUMPUR (Sep 12): Pasukhas Group Bhd has secured a contract to sell one vessel of steam coal in South Kalimantan, Indonesia for US$4.93 million (RM20.44 million).
0177 BSMAF 1818

 
Pasukhas aims to expand coal trading, power plant businesses

2018-08-07 theedgemarkets
KUALA LUMPUR: Construction company Pasukhas Group Bhd said its new venture into coal trading will soon become a major revenue stream for the financial year ending Dec 31, 2018 (FY18), contributing revenue of RM150 million in FY18.
0177

 
KLCI seen trending sideways, immediate support at 1,764

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI is seen trending sideways today with immediate support at 1,764, despite the firmer overnight close at most global markets, as buying support at the local bourse is likely to be lukewarm.
0177 5106 5260 7168 1481 9466

 
SD Plantation, PRG, Pasukhas, KKB, SKH, Axis REIT, OWG, MCT and Advance Synergy

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): Based on corporate announcements and news flow today, stocks in focus for Tuesday (Aug 7) may include the following: Sime Darby Plantation Bhd, PRG Holdings Bhd, Pasukhas Group Bhd, KKB Engineering Bhd, SKH Consortium Bhd, Axis Real Estate Investment Trust, Only World Group Holdings Bhd, MCT Bhd and Advance Synergy Bhd.
0177 5106 5260 7168 BSMAF 1481 9466 1818

 
Pasukhas aims to comply with Bumiputra Equity Requirements by year end

2018-08-06 theedgemarkets
KUALA LUMPUR (Aug 6): Pasukhas Group Bhd targets to comply with the Bumiputra Equity Requirements by year end.
0177

 
Trading ideas: Crest Builder, Pasukhas, Tien Wah, PUC, Comintel

2018-03-21 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Crest Builder Holdings Bhd , Pasukhas Group Bhd , Tien Wah Press Holdings Bhd , PUC Bhd and Comintel Corp Bhd to be among the stocks to watch today.
0177 8591 7374

4
Pasukhas wins RM41mil job from Paramount

2018-03-20 thestar.com.my
PETALING JAYA: Pasukhas Group Bhd (PGB) has won a contract from Paramount Property Construction Sdn Bhd to undertake superstructure works for hotels and a service apartment in Shah Alam, Selangor, totalling RM41mil.
0177 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...